Windhover Information Inc. - Health Care Business Intelligence
Delivering essential analysis and insights to top health care executives, investment professionals, and industry consultants

By Roger Longman, IN VIVO 5/1/2007
IN VIVO -- With clinical failure rates rising industry-wide, a skunkworks at Lilly, called Chorus, has been trying to boost likely-to-succeed shots on goal by getting compounds to human proof-of-concept far faster and cheaper than the internal organization. Lilly's R&D group is skeptical about the program, even anxious -- one reason Chorus has teamed up with a major venture fund to get more molecules to test. If the program works, will Lilly embrace it - or will its venture partner reap the rewards?
For $125, purchase this 4468-word article as a PDF, and receive immediate delivery via email. View a complete sample article.
Questions? Call Toll Free (800) 332-2181 or (908) 547-2159.
